Royal Bank of Canada Buys 24,375 Shares of PROCEPT BioRobotics Corporation $PRCT

Royal Bank of Canada increased its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 167.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,962 shares of the company’s stock after purchasing an additional 24,375 shares during the quarter. Royal Bank of Canada’s holdings in PROCEPT BioRobotics were worth $975,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in PRCT. Prosight Management LP boosted its stake in PROCEPT BioRobotics by 1,692.4% in the 4th quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after purchasing an additional 1,303,009 shares during the period. Alliancebernstein L.P. increased its position in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after buying an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after buying an additional 1,218,815 shares during the period. UBS Group AG lifted its holdings in shares of PROCEPT BioRobotics by 129.3% in the third quarter. UBS Group AG now owns 944,545 shares of the company’s stock worth $33,711,000 after buying an additional 532,530 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of PROCEPT BioRobotics by 690.0% in the fourth quarter. Millennium Management LLC now owns 383,137 shares of the company’s stock valued at $12,053,000 after acquiring an additional 448,077 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Up 4.6%

PRCT stock opened at $21.68 on Friday. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average is $20.40 and its 200 day moving average is $24.20. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -11.18 and a beta of 0.89. PROCEPT BioRobotics Corporation has a 1-year low of $16.67 and a 1-year high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. During the same quarter in the previous year, the firm earned ($0.35) earnings per share. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. Sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on PRCT shares. Piper Sandler reduced their price objective on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Citigroup cut shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. William Blair downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Wells Fargo & Company cut shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.00.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases of PROCEPT stock from February 28, 2024, through February 25, 2026. These announcements are largely duplicative investor-solicitation notices rather than new company disclosures. Kaplan Fox class-action deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT failed to disclose inventory problems, including excess customer inventory tied to late-quarter bulk discounts, while investors focused on handpiece sales as a measure of procedure demand. The allegations claim that later revelations led to a substantial stock decline, including an approximately 18% drop referenced in one notice and a decline of more than 75% from the class-period high in another. Hagens Berman PROCEPT class-action notice
• Negative Sentiment: The litigation introduces potential legal costs, reputational risk and further scrutiny of PROCEPT’s sales practices, inventory management and underlying procedure demand. The notices do not establish wrongdoing, and no new operational update or company response was provided in the supplied articles. Kahn Swick and Foti PROCEPT securities-fraud notice

Insider Buying and Selling at PROCEPT BioRobotics

In related news, CEO Larry L. Wood acquired 23,900 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the acquisition, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 1,000 shares of company stock worth $28,480. Company insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.